Eagle Biosciences is thrilled to introduce the Anti-MyD88 L265P Antibody to our product lineup! This powerful tool can significantly enhance your lymphoma research.
Application
MyD88 L265P is a prevalent driver mutation in B-cell lymphomas, contributing to oncogenic signaling by activating BTK, HCK, NFkB, and JAK-STAT3 pathways. This mutation is linked to a poor prognosis and is frequently observed in:
- 90% of Waldenström’s macroglobulinemia (WM) cases
- 50-80% of IgM monoclonal gammopathy of undetermined significance (IgM-MGUS) cases
- 29% of diffuse large B-cell lymphomas (DLBCL) cases
WM and the aggressive activated B-cell-like (ABC) subtype of DLBCL remain incurable, making the tumor-specific MyD88 L265P mutation a valuable prognostic marker and a promising target for novel therapies.
Background
The MyD88 gene encodes a cytosolic adapter protein vital for both innate and adaptive immune responses. This protein acts as a crucial signal transducer in the interleukin-1 and Toll-like receptor signaling pathways, which regulate the activation of numerous proinflammatory genes. The protein includes an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in this gene are more susceptible to pyogenic bacterial infections. Multiple transcript variants result from alternative splicing.
If you have any questions about this product or any of our other offerings, contact us here.